A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma

European Journal of Cancer

Volumn 34, Issue 13, 1998, Pages 2027-2031

  Yeo, W ^a   Leung, T W T ^a   Chan, A T C ^a   Chiu, S K W ^a   Yu, P ^a   Mok, T S K ^a   Johnson, P J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Carboplatin; Metastatic recurrent nasopharyngeal carcinoma; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; NASOPHARYNX CARCINOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032402238     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00280-9     Document Type: Article

References (30)

1. 1. Cvitkovic E, Bauchouchi M, Armand JP. Nasopharyngeal carcinoma. Biology, natural history, and therapeutic implications. Hematol Oncol Clin North Am 1991, 5(4), 821-838.
2. 2. Ahmad A, Stefani S. Distant metastases of nasopharyngeal carcinoma. A study of 256 male patients. J Surg Oncol 1986, 33, 1954-1957.
3. 3. Choo R, Tannock I. Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. Cancer 1991, 68, 2120-2124.
4. 4. Decker DA, Drelichman A, Al-Sarraf M, et al. Nasopharyngeal carcinoma. A ten year experience. Cancer 1983, 52, 602-605.
5. 5. Yeo W, Leung WT, Leung SF, et al. Carboplatin and 5-fluorouracil combination chemotherapy in metastatic nasopharyngeal carcinoma. Cancer, Chemother Pharmacol 1996, 38, 466-470.
6. 6. Calvert AH, Newell DR, Gumbrell LS, et al. Carboplatin dosage: prospective evaluation of simple formula based on renal function. J Clin Oncol 1989, 7, 1748-1756.
7. 7. Egorin MJ, Reyno LM, Canetta RM, et al. Modelling toxicity and responses in carboplatin-based combination chemotherapy. Semin Oncol 1994, 21(5), 7-19.
8. 8. Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992, 10(4), 520-528.
9. 9. McGuire WP. Experimental chemotherapy. Hematol Oncol Clin North Am 1992, 6, 927-940.
10. 10. Holms FA, Waiters RS, Theriault RL, et al. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1992, 83, 1797-1805.
11. 11. Forastiere AA. Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck. Semin Oncol 1993, 20, 56-60.
12. 12. Murphy WK, Fosella FV, Winn RJ, et al. Phase II study of Taxol in patients with untreated non-small cell lung cancer. J Natl Cancer Inst 1993, 82, 384-388.
13. 13. Jett JR, Kirshling RJ, Jung S-H, Marks RS. A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group. Semin Oncol 1995, 22(3), 75-77.
14. 14. Shanmugaratnam K. Histological typing of upper respiratory tract tumours. International Histological Typing of Tumours. Geneva, World Health Organisation, 1978, 19-21.
15. 15. World Health Organisation Handbook for Reporting Results of Cancer Treatment. Geneva, World Health Organisation, 1979.
16. 16. Ho HC. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1978, 4(3), 183-198.
17. 17. Teo PML, Tsoa SY, Ho MC, et al. A proposed modification of the Ho stage classification for nasopharyngeal carcinoma. Radiother Oncol 1991, 21, 19-23.
18. 18. Boussen H, Cvitkovic E, Wendling JL, et al. Chemotherapy for metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin and fluorouracil. J Clin Oncol 1991, 9(9), 1675-1681.
19. 19. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group Study. J Clin Oncol 1992, 10, 1245-1251.
20. 20. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992, 10, 257-263.
21. 21. Forastiere A. Overview of platinum chemotherapy in head and neck cancer. Semin Oncol 1994, 21(5), 20-27.
22. 22. Yokes EE, Haraf DJ, Stenson K, et al. The role of paclitaxel in the treatment of head and neck cancer. Semin Oncol 1995, 22(5), 8-12.
23. 23. Forastiere AA. Current and future trials of Taxol (paclitaxel) in head and neck cancer. Ann Oncol 1994, 5(Suppl. 6), S51-S54.
24. 24. Hitt R, Hornedo J, Colomer R, et al. Phase I-II study of escalating doses of taxol + cisplatin with G-CSF (Filgrastim) as first-line therapy for head and neck carcinomas: preliminary results. Proc Am Soc Clin Oncol 1995, 14, 300 (Abstr. 868).
25. 25. Au E, Ang PT, Chua EJ. Paclitaxel in metastatic nasopharyngeal cancer. Program/Proc Am Soc Clin Oncol 1996, 15, 322.
26. 26. Aisner J, Belani CP, Kearns C, et al. Feasibility and pharmacokinetics of paclitaxel, carboplatin and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer. Semin Oncol 1995, 22(Suppl. 12), 17-21.
27. 27. Forastiere AA, Leong T, Murphy B, et al. A phase III trial of high dose paclitaxel + cisplatin + G-CSF versus low-dose paclitaxel + cisplatin in patients with advanced squamous cell carcinoma of the head and neck (HNSCC): an Eastern Cooperative Oncology Group trial. Program/Proc Am Soc Clin Oncol 1997, 16, 384a.
28. 28. Fountzilas G, Athanassiadis A, Samantas E, et al. Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study. Semin Oncol 1997, 24(1)(Suppl 2), S2-65-S2-67.
29. 29. Tan EH, Khoo KS, Au E. Phase II trial of paclitaxel and carboplatin in patients with metastatic undifferentiated nasopharyngeal carcinoma. Program/Free Am Soc Clin Oncol 1998, 17, 383a.
30. 30. Creaven P, Raghavan D, Pendyala L, et al. Phase I study of paclitaxel and carboplatin: implications for trials in head and neck cancer. Semin Oncol 1995, 22(Suppl. 12), 13-16.